Three years after Sanofi signed on to back Cambridge, MA-based Warp Drive Bio, taking an option to buy, the pharma giant has stepped back up to retool the terms, opting for a 5-year collaboration potentially worth $750 million while leaving the biotech free to pursue its own independent future.
Moderna Therapeutics, a high-profile private biotech with scores of preclinical projects, is finally moving toward human trials, recruiting one of the world's largest CROs to help get its much-hyped pipeline moving.
The R&D collaboration efforts keeping coming from Osaka-based Takeda Pharmaceutical with a push now on Parkinson's disease with NsGene looking at a regenerative therapy involving a biotherapeutic brain implant.
Pharma giant Johnson & Johnson said it has licensed the rights to various liver treatments from a unit of Hong Kong-based Sino Biopharmaceutical that it hopes will help lead to a cure for chronic hepatitis B.
Belgian drugmaker UCB recruited Evotec to oversee its library of chemical compounds, enlisting the German company's expertise in hopes of easing the drug discovery process.
Johnson & Johnson's latest spate of partnerships highlights its willingness to go anywhere necessary to find all the pieces it needs to create a therapeutic cocktail that can provide a functional cure for hepatitis B.
Chinese property and investment company Wanda Group is jumping on the healthcare bandwagon on the mainland with an investment of $2.3 billion that it will use to build three private hospitals in Shanghai, Chengdu and Qingdao that will be managed by Britain's International Hospital Group.
Osaka-based Takeda Pharmaceutical has taken its second effort in a month in gastrointestinal disorders, this time by a pact to study gene sequences of microbiomes to find new therapy pathways with France's Enterome Bioscience.
Qualcomm and Novartis are working together to develop a next-gen connected version of the pharma's Breezhaler device that's used across its entire chronic obstructive pulmonary disease drug portfolio.
Japanese drugmaker Takeda is deepening its work in microbiomics, signing a drug discovery deal with France's Enterome Bioscience in hopes of spotlighting new treatments for gastrointestinal disorders.